05.07.2022 15:04:49

CureVac Sues BioNTech In Germany Seeking Fair Compensation For Patent Infringement

(RTTNews) - CureVac N.V. (CVAC) has filed a patent infringement lawsuit in Germany against BioNTech to assert the company's intellectual property rights which contributed to COVID-19 vaccine development. The company said the CureVac intellectual property portfolio protects multiple inventions that are considered essential to the design and development of BioNTech's SARS CoV-2 mRNA vaccine, among others.

CureVac believes its intellectual property rights need to be acknowledged and respected in the form of a fair compensation to reinvest into the further advancement of mRNA technology.

Analysen zu BioNTech (ADRs)mehr Analysen

17.12.24 BioNTech Neutral JP Morgan Chase & Co.
12.12.24 BioNTech Buy Jefferies & Company Inc.
11.12.24 BioNTech Neutral JP Morgan Chase & Co.
27.11.24 BioNTech Buy Deutsche Bank AG
26.11.24 BioNTech Buy Goldman Sachs Group Inc.
Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

BioNTech (ADRs) 108,30 -1,10% BioNTech (ADRs)
CureVac 3,02 -0,98% CureVac